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Novel roles for class II 
Phosphoinositide 3-Kinase C2β in 
signalling pathways involved in 
prostate cancer cell invasion
Ioanna Mavrommati1,†, Ouma Cisse1, Marco Falasca1,2 & Tania Maffucci1
Phosphoinositide 3-kinases (PI3Ks) regulate several cellular functions such as proliferation, growth, 
survival and migration. The eight PI3K isoforms are grouped into three classes and the three enzymes 
belonging to the class II subfamily (PI3K-C2α, β and γ) are the least investigated amongst all PI3Ks. 
Interest on these isoforms has been recently fuelled by the identification of specific physiological roles 
for class II PI3Ks and by accumulating evidence indicating their involvement in human diseases. While it 
is now established that these isoforms can regulate distinct cellular functions compared to other PI3Ks, 
there is still a limited understanding of the signalling pathways that can be specifically regulated by 
class II PI3Ks. Here we show that PI3K-C2β regulates mitogen-activated protein kinase kinase (MEK1/2) 
and extracellular signal-regulated kinase (ERK1/2) activation in prostate cancer (PCa) cells. We further 
demonstrate that MEK/ERK and PI3K-C2β are required for PCa cell invasion but not proliferation. In 
addition we show that PI3K-C2β but not MEK/ERK regulates PCa cell migration as well as expression 
of the transcription factor Slug. These data identify novel signalling pathways specifically regulated by 
PI3K-C2β and they further identify this enzyme as a key regulator of PCa cell migration and invasion.
Phosphoinositide 3-kinases (PI3Ks), the lipid kinases that catalyse the synthesis of the phosphoinositides phos-
phatidylinositol 3-phosphate, phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate 
[PtdIns(3,4,5)P3], have a well-established role in regulation of several cellular processes, including cell prolifera-
tion, growth, survival, migration and metabolism1–3. Deregulation of PI3Ks-dependent signals is associated with 
several diseases including cancer4–8 and indeed inhibitors of this pathway have been developed as anti-cancer 
drugs and are currently in clinical trials9–11. Unfortunately the use of these inhibitors has also led to the discovery 
of compensatory mechanisms that reduce their therapeutic efficiency12,13. As a consequence an increasing interest 
has emerged to better define the potential contribution of each of the eight mammalian PI3K isoforms to cancer 
development and progression and ultimately to identify more selective and targeted therapeutic strategies2,14,15. 
Generation of isoform specific knock-out and knock-in mice and the development of isoform-specific inhibitors 
have greatly improved our knowledge of the physiological roles and the cellular functions that are specifically 
regulated by each PI3K16,17. On the other hand much less is known about specific signalling pathways that can be 
activated selectively by each PI3K isoform.
The three isoforms grouped into the class II subfamily (PI3K-C2α , β and γ ) have been the least investigated 
amongst all PI3Ks for many years2,18. Lately interest on these enzymes has progressively increased and indeed 
recent studies have shed light into their specific physiological roles17. Attempt to generate homozygous PI3K-C2α 
knock-out19–21 or kinase-inactivating knock-in22 mice resulted in embryo lethality revealing a specific require-
ment for this enzyme in embryo development. On the other hand both PI3K-C2β −/− 23 and PI3K-C2γ −/− 24 mice 
were viable supporting the conclusion that the class II isoforms have distinct cellular functions. Further investi-
gation identified a pivotal role for PI3K-C2α in endothelial cells, angiogenesis and vascular barrier function19, 
in regulation of primary cilium function20 and, more recently, in regulation of platelets membrane structure, 
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morphology and adhesion21,22. Investigation of PI3K-C2β −/− mice established that the enzyme is not required 
for growth, differentiation, barrier function and wound healing in the epidermis23. PI3K-C2γ appears to have a 
specific role in glucose homeostasis regulation since PI3K-C2γ −/− mice develop hyperlipidemia, adiposity and 
insulin resistance with age or following high fat diet24. These studies have all reinforced the conclusion that each 
class II PI3K isoforms can regulate distinct cellular functions compared to other PI3Ks and have fuelled interest 
towards a better characterisation of these enzymes. A better understanding of potential contribution of class II 
PI3Ks to human diseases is also urged by accumulating evidence indicating a role for some of these enzymes 
in cancer. It has been reported that subsets of tumour and cell lines from small cell lung cancer (SCLC), acute 
myeloid leukemia, glioblastoma multiforme, medulloblastoma25 as well as primary neuroblastoma tumours and 
cell lines25,26 are characterised by increased levels of PI3K-C2β . Consistently, gene expression profiling indicated 
increased expression of PI3K-C2β in acute lymphocytic leukemia, acute myeloid leukemia and glioblastoma27–29 
and recurrent mutations (12.9%) in PIK3C2B have been observed in lung cancer30. Furthermore PI3K-C2β has 
been implicated in cancer cell migration31–33 and in neuroblastoma tumourigenesis34. Importantly inhibition of 
PI3K-C2β has been shown to inhibit early stage of neuroblastoma formation34 and ovarian cancer metastasis for-
mation33 in animal models, supporting the conclusion that this enzyme may represent a novel interesting target 
in anti-cancer therapy. Despite this evidence there is still a very limited understanding of the signalling pathways 
that can be specifically regulated by PI3K-C2β .
Here we show that PI3K-C2β regulates mitogen-activated protein kinase kinase (MEK1/2) and extracel-
lular signal-regulated kinase (ERK1/2) activation induced by foetal bovine serum (FBS) or epidermal growth 
factor (EGF) in prostate cancer (PCa) cell lines. Inhibition of MEK/ERK activation as well as downregulation 
of PI3K-C2β does not affect cell proliferation while specifically inhibiting cell invasion. We further show that 
PI3K-C2β regulates FBS-induced PCa cell migration in a mechanism that does not appear to involve MEK/ERK 
activation. Investigation of additional signalling pathways modulated by PI3K-C2β reveals a role for this enzyme 
in regulating the expression levels of the transcription factor Slug. These data identify novel signalling pathways 
specifically regulated by PI3K-C2β and involved in migration and invasion of PCa cells.
Results
PI3K-C2β regulates MEK/ERK activation in PCa cells. The signalling pathways specifically regulated 
by PI3K-C2β are still not completely defined. While previous studies have mainly focussed their attention on its 
potential contribution to activation of the well established class I PI3K target Akt2,34,35 and Rho GTPAses2,32,36,37 
little is known about other kinases potentially regulated by this enzyme. We therefore decided to investigate the 
potential role of PI3K-C2β on activation of a panel of 43 distinct kinases and 2 related proteins using a phosphoki-
nase antibody array. The choice of the cellular model was prompted by a recent study suggesting a potential asso-
ciation between PI3K-C2β and PCa risk38. First we analysed the expression levels of PI3K-C2β in three distinct 
PCa cell lines compared to PNT2, an immortalised prostate cell line. PI3K-C2β was highly expressed in PC3 and 
LNCaP cell lines, both lacking the tumour suppressor phosphatase and tensin homolog (PTEN), the phosphatase 
responsible for dephosphorylation of PtdIns(3,4,5)P3, compared to the PTEN expressing PCa cell line DU145 and 
to PNT2 cells (Fig. 1a). Interestingly we also noticed that PI3K-C2β was barely detectable in DU145 and PNT2 
when cells were lysed with 1% Triton X-100 whereas it was clearly observed when cells were lysed with 2% SDS 
(Fig. 1a), suggesting a specific localisation of the enzyme within Triton-insoluble cellular fractions in these cells.
Based on PI3K-C2β expression we selected PC3 cells for phosphokinase antibody array analysis. We reasoned 
that the constitutive hyperactivation of the class I PI3Ks-dependent pathways due to the lack of PTEN could facil-
itate the identification of pathways specifically modulated by PI3K-C2β upon growth factor stimulation. To deter-
mine the role of PI3K-C2β we generated stable PC3 cell lines by transfecting parental cells with a pSuper vector 
carrying a shRNA specifically targeting the enzyme. Control cells were transfected with a vector containing a non 
targeting shRNA. Cell populations expressing the PI3K-C2β -targeting shRNA or control shRNA were selected 
by incubation in media supplemented with puromycin and then allowed to grow as single clones. Four distinct 
knockdown clones were then selected, all displaying a high efficiency of PI3K-C2β downregulation (sh PI3K-C2β , 
Fig. 1b, Supplementary Fig. S1a) as well as four control clones (sh scrambled, Fig. 1b, Supplementary Fig. S1a). 
No effect on the expression levels of the class I isoforms p110α , p110β and the class II enzyme PI3K-C2α was 
detected in the knockdown clones (Supplementary Fig. S1b,c) and no difference in the expression of PI3K-C2β 
between control clones and parental cells was observed (Fig. 1b).
Once stable cell lines were established one sh PI3K-C2β clone and one sh scrambled clone were serum starved 
overnight and either left untreated or stimulated with DMEM containing 10% FBS for 10 min. Activation of a 
panel of kinases was then analysed in the corresponding lysates (Supplementary Fig. S1d). Densitometry analysis 
of the phosphoarray indicated only slight differences in the FBS-induced activation of the classical class I PI3K 
signalling pathways (Supplementary Fig. S1e). On the other hand a clear inhibition of FBS-induced phosphoryl-
ation of some members of the mitogen-activated protein kinases (MAPK) family was observed in cells lacking 
PI3K-C2β (Supplementary Fig. S1f). In particular FBS-induced p38α and MEK1/2 phosphorylation appeared to 
be strongly reduced in cells lacking PI3K-C2β (Supplementary Fig. S1f).
Stable PI3K-C2β downregulation inhibits MEK and ERK activation. To validate the results of 
the array we then performed a time course experiment using two distinct knockdown clones and two control 
clones (Supplementary Fig. S1g,h). Data revealed a very rapid and transient phosphorylation of ERK1/2 at resi-
dues Thr202/Tyr204 and a more sustained phosphorylation of MEK1/2 at residues Ser217/221 (Supplementary 
Fig. S1g,h). Importantly FBS-induced phosphorylation of both MEK1/2 and ERK1/2 was reduced in cells 
lacking PI3K-C2β (Supplementary Fig. S1g,h). Validation of these results in distinct PI3K-C2β knockdown 
clones indicated a significant reduction of MEK1/2 phosphorylation upon 5 and 10 min of FBS stimulation 
(Fig. 1c,d), as confirmed by densitometry analysis (Fig. 1e,f). Similarly a clear inhibition of FBS-induced ERK1/2 
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Figure 1. PI3K-C2β is required for FBS-induced MAPK activation. (a) Representative blot of PI3K-C2β 
and PTEN levels in the indicated prostate cell lines upon lysis with 1% Triton X-100 or 2% SDS. Tubulin or 
Actin were used as loading control. (b) Stable PC3 clones expressing a specific shRNA targeting PI3K-C2β or 
a control shRNA (sh scrambled) were generated as described in the Methods. Representative blots showing 
expression levels of PI3K-C2β in the indicated stable PC3 cells. Numbers indicate the specific clone. (c–j) The 
indicated PC3 stable clones were serum starved overnight and then stimulated with FBS for the indicated times. 
Phosphorylation of MEK1/2 at residues Ser217/221 (c–f) and ERK1/2 at residues Thr202/Tyr204 (g–j) was 
assessed by Western blotting. Tubulin was used as loading control. In some experiments membranes incubated 
with pERK1/2 were stripped and then incubated with antibody recognising total ERK2. Representative blots 
are shown. Results from densitometry analysis are expressed as fold change of the specific sh scrambled clone 
used in each experiment and are means ± s.e.m. from the following number of experiments: (e): n = 3 (PC3 and 
clone 4), n = 4 (clones 1,3), n = 2 (clone 2); (f): n = 3 (PC3, clones 1,4), n = 4 (clone 2), n = 6 (clone 3); (i): n = 2 
(PC3, clones 1,2,4), n = 3 (clone 3); (j): n = 3 (PC3, clone 1), n = 12 (clone 2), n = 11 (clone 3), n = 2 (clone 4). 
*p < 0.05, **p < 0.01, ***p < 0.001.
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phosphorylation was detected in cells lacking PI3K-C2β (Fig. 1g–j). No major differences were observed in 
MEK1/2 and ERK/12 phosphorylation between parental and control sh scrambled cells (Fig. 1c–j).
To further validate the role of PI3K-C2β in ERK1/2 activation stable PC3 clones were stimulated with epi-
dermal growth factor (EGF). Consistent with data obtained upon FBS stimulation, EGF-induced MEK1/2 
(Fig. 2a,b) and ERK1/2 (Fig. 2c,d) phosphorylation was strongly reduced in cells lacking PI3K-C2β . Importantly 
the reduced phosphorylation was not due to reduced total ERK levels in sh PI3K-C2β stable cell lines (Fig. 2e–h, 
Supplementary Fig. S2a).
Taken together these data indicate that PI3K-C2β regulates MEK/ERK activation upon FBS and EGF 
stimulation.
Figure 2. PI3K-C2β regulates EGF- and FBS-dependent MAPK activation. (a–d) The indicated PC3 stable 
clones were serum starved overnight and then stimulated with 20 ng/ml EGF for 10 min. In some of these 
experiments, FBS was used as positive control. Phosphorylation of MEK1/2 (a,b) and ERK1/2 (c,d) was assessed 
by Western blotting. Results from densitometry analysis are expressed as fold change of the sh scrambled clone 
and are means ± s.e.m. from the following number of experiments: (b) n = 2 (EGF), n = 1 (FBS); (d): n = 3 
(EGF), n = 2 (FBS). *p < 0.05. (e,f) The indicated PC3 stable clones were treated as above. Membranes were then 
stripped and re-incubated with total ERK2. (g,h) Total levels of ERK2 were assessed in PC3 and in the indicated 
stable clones. Results from densitometry analysis are expressed as fold change of sh scrambled clone 3 and are 
means ± s.e.m. from the following number of experiments: n = 2 (sh scrambled clone 1, sh PI3K-C2β clone 1), 
n = 3 (sh scrambled clone 2), n = 4 (PC3), n = 5 (sh scrambled clone 3, sh PI3K-C2β clones 2 and 3). (i–m) PC3 
cells were transfected with two specific siRNAs targeting PI3K-C2β and a non targeting, negative control siRNA 
(si NC), serum starved overnight the following day and then stimulated with FBS for 10 min. Phosphorylation 
of MEK1/2 (i,j), phosphorylation of ERK1/2 (k,l) and total levels of ERK2 (m) were assessed by Western 
blotting. Results from densitometry analysis are expressed as fold change of cells transfected with si NC and are 
means ± s.e.m. from n = 3 (j), n = 5–6 (l) independent experiments. *p < 0.05, **p < 0.01. (n,o) LNCaP cells 
were transfected with the indicated siRNAs, serum starved and then stimulated with 20 ng/ml EGF for 10 min. 
Phosphorylation of ERK1/2 was assessed by Western blotting. Results from densitometry are means ± s.e.m. 
from n = 3 independent experiments. *p < 0.05, ***p < 0.001. In all panels representative blots are shown. 
Where indicated tubulin was used as loading control and levels of PI3K-C2β were also assessed in the same or 
parallel gels.
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Transient PI3K-C2β downregulation inhibits MEK1/2 and ERK1/2 activation. In order to rule out 
any potential non-specific effect due to the stable downregulation of PI3K-C2β we next investigated the effect of 
transient downregulation of the enzyme on MEK1/2 and ERK1/2 phosphorylation. Consistent with data obtained 
using the stable clones, PI3K-C2β downregulation using two distinct siRNAs significantly inhibited FBS-induced 
MEK1/2 (Fig. 2i,j) and ERK1/2 phosphorylation (Fig. 2k,l) compared to cells transfected with a non targeting, 
negative control siRNA (si NC). As for stable cells, transient downregulation of PI3K-C2β did not reduce total 
ERK levels (Fig. 2m).
To further investigate the role of PI3K-C2β in MAPK activation in PCa cells, we determined the effect of 
its transient downregulation in LNCaP cells that express high levels of PI3K-C2β and do not express PTEN 
(Fig. 1a). Preliminary experiments revealed a strong phosphorylation of ERK1/2 upon EGF stimulation in these 
cells (Supplementary Fig. S2b). Consistent with data in PC3, the EGF-induced ERK1/2 phosphorylation was sig-
nificantly reduced in LNCaP upon transient downregulation of PI3K-C2β with two distinct siRNAs (Fig. 2n,o).
We next investigated whether other PI3K isoforms were also involved in regulation of ERK phosphorylation. 
To this end PC3 cells were treated with the PI3K inhibitor LY294002 before stimulation with FBS or EGF. The 
concentration of LY294002 used (5 μM) is reported not to affect PI3K-C2β activation31,39 while being able to 
inhibit class I and class III PI3K isoforms. Indeed treatment of cells with LY294002 (5 μM) clearly inhibited phos-
phorylation of Akt at its residue Ser473 (Supplementary Fig. S2c–e). In contrast the inhibitor did not affect either 
the FBS- or the EGF-induced ERK1/2 phosphorylation (Supplementary Fig. S2f–h) suggesting that class I and 
class III PI3Ks are not involved in ERK1/2 activation in PC3 cells.
Taken together these data indicate a specific role for PI3K-C2β in regulation of MEK/ERK activation in PCa 
cells.
The PI3K-C2β/ERK pathway does not regulate cell growth in PCa cells. We next investigated 
whether the PI3K-C2β -dependent MEK/ERK activation had a role on PCa cell growth. Interestingly, incubation 
of PC3 cells for 72 h in growth media supplemented with the MEK1/2 inhibitor U0126 did not reduce the number 
of cells (Fig. 3a). Similarly transient downregulation of PI3K-C2β did not reduce the number of cells as deter-
mined 72 h following transfection (Fig. 3b). Efficiency of PI3K-C2β downregulation was assessed by Western 
blotting analysis (Fig. 3c). Consistent with this, cell counting (Fig. 3d) and MTT assays (Fig. 3e) revealed no 
difference in proliferation in growth media between parental PC3, two distinct sh scrambled and two distinct 
sh PI3K-C2β stable clones. Levels of PI3K-C2β in the indicated clones was assessed by Western blotting analy-
sis (Fig. 3f). Furthermore no statistically significant difference in the percentage of cells in the G1, S and G2/M 
phases of the cell cycle (Fig. 3g) or in the percentage of apoptotic cells (Fig. 3h) was detected in PC3 cells upon 
transient downregulation of PI3K-C2β . As a control downregulation of the class I PI3K isoform p110β performed 
in parallel was clearly able to induce apoptosis in these cells (Fig. 3h). Western blotting analysis confirmed effi-
cient downregulation of PI3K-C2β and p110β (Fig. 3i).
Taken together these data indicate that the PI3K-C2β /MEK/ERK pathway does not regulate PC3 cell prolifer-
ation, at least in normal growing conditions.
MEK/ERK and PI3K-C2β are involved in PCa invasion. Although the MEK/ERK pathway is usually 
associated with cell proliferation data in literature also indicate a role for these kinases in regulation of cell motil-
ity and migration. We therefore decided to determine whether this pathway was required for PC3 cell invasion. 
Inhibition of MEK1/2 with the specific inhibitor U0126 significantly reduced FBS-induced cell invasion (Fig. 4a) 
without affecting cell proliferation assessed in parallel (Fig. 4b). Efficiency of the inhibitor was confirmed by 
Western blotting analysis of lysates from cells plated in parallel and stimulated with FBS (Fig. 4c). These data 
indicate a role for MEK/ERK in PCa cell invasion.
We then investigated whether PI3K-C2β was also involved in this process. As shown in Fig. 4d,e, transient 
downregulation of PI3K-C2β with two distinct siRNAs strongly reduced FBS-induced cell invasion in PC3 
cells. No statistically significant difference was observed in invasion of cells transfected with control siRNA (si 
NC) compared to cells (control) treated with the transfection reagent alone (Fig. 4d,e). A strong inhibition of 
FBS-induced invasion was also detected in three distinct sh PI3K-C2β stable clones compared to control sh 
scrambled cells (Fig. 4f,g). Representative images are shown in Fig. 4f. Quantification of these assays indicated a 
very strong inhibition of invasion in cells lacking PI3K-C2β (Fig. 4g). No difference was detected between sta-
ble control cells compared to parental PC3 cells (Fig. 4g). On the other hand downregulation of PI3K-C2β did 
not affect basal invasion induced by Matrigel alone (Fig. 4h), indicating a specific role for PI3K-C2β in growth 
factors-induced cell invasion. Consistent with this, we observed that EGF-induced invasion was also reduced in 
cells lacking PI3K-C2β (Fig. 4i). In addition downregulation of PI3K-C2β using two distinct siRNAs reduced 
the FBS-induced invasion in LNCaP cells (Fig. 4j). Efficient downregulation of PI3K-C2β in this cell line was 
confirmed by Western blotting (Fig. 4k).
Taken together these data indicate that MEK/ERK and PI3K-C2β are required for PCa cell invasion.
PI3K-C2β regulates PCa cell migration. Several studies have reported that PI3K-C2β regulates cell 
migration in different cell types31–33,37,40. Therefore we next investigated whether the effect of PI3K-C2β down-
regulation on PCa cell invasion was due to a specific role of the enzyme in regulation of cell migration in these 
cells. Transwell assays revealed a clear reduction in FBS-induced migration of PC3 cells upon downregulation 
of PI3K-C2β using two distinct siRNAs (Fig. 5a,b). Similarly, reduced migration was observed in two distinct 
sh PI3K-C2β clones compared to sh scrambled cell lines (Fig. 5c). Representative images of migrated cells 
are also shown in Fig. 5c. Consistent with data from Transwell assays, cells lacking PI3K-C2β also displayed 
impaired FBS-induced migration in wound healing assays (Fig. 5d,e). On the other hand no major differences 
were detected in the distance and velocity of parental and stable cell lines in single cell-motility assays (Fig. 5f), 
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Figure 3. MEK/ERK and PI3K-C2β are not required for PCa cell proliferation. (a) PC3 cells were 
incubated in growth media supplemented with MEK1/2 inhibitor U0126 (25 μM) or vehicle control (DMSO) 
for 72 h before counting. Data are expressed as fold change of number of cells treated with DMSO and are 
means ± s.e.m. from n = 3 independent experiments. (b,c) PC3 cells were transiently transfected with a specific 
siRNA targeting PI3K-C2β (sequence 1), a non targeting, negative control siRNA (si NC) or transfection 
reagent (control) alone. The number of cells was determined by manual counting after 72 h in growth media. 
Data are expressed as fold change of number of control cells and are means ± s.e.m. of n = 4 independent 
experiments. Efficient downregulation of PI3K-C2β was confirmed by Western blotting analysis. Tubulin was 
used as loading control. (d) Data from cell counting are expressed as fold change of number of cells plated at day 
0 and are means ± s.e.m. of n = 7 (PC3), n = 11 (sh scrambled clone 2), n = 3–4 (sh scrambled clone 3), n = 8 
(sh PI3K-C2β clone 2) and n = 5–6 (sh PI3K-C2β clone 3) independent experiments. (e) Data from MTT assay 
are expressed as fold change of absorbance determined at day 1 and are means ± s.e.m. of n = 3–4 experiments. 
(f) Representative blot showing expression levels of PI3K-C2β in the indicated cell lines. (g) PC3 cells were 
transiently transfected as before and fixed after 72 h. Cell cycle analysis was performed by FACS as described 
in the Methods section. Data are expressed as percentage of cells in the distinct phases and are means ± s.e.m. 
of n = 4 independent experiments. (h) PC3 cells were transiently transfected with the indicated siRNAs. The 
percentage of apoptotic cells was determined 48 h after transfection by Annexin V/FACS analysis as described 
in the Methods section. Data are expressed as percentage of early + late apoptotic cells and are means ± s.e.m. 
of n = 3–4 independent experiments. Data from one experiment with siRNA PI3K-C2β (sequence 1) and two 
experiments with siRNA PI3K-C2β (sequence 2) are pulled together. (i) Efficiency of PI3K-C2β and p110β 
downregulation was assessed by Western blotting.
www.nature.com/scientificreports/
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consistent with previous observations in endothelial cells40. Similarly downregulation of PI3K-C2β did not affect 
migration induced by Type I collagen (Fig. 5g), indicating a specific role for this enzyme in FBS-dependent PCa 
cell migration.
We then determined whether MEK/ERK were also involved in this process. Interestingly treatment of cells 
with the MEK1/2 inhibitor U0126 did not affect the FBS-induced migration of PC3 cells assessed by Transwell 
assays (Fig. 5h). Consistent with data presented above (Figs 3a and 4b) incubation with the inhibitor did not affect 
cell numbers (Fig. 5i). Efficiency of the inhibitor was confirmed in experiments performed in parallel (Fig. 5j). 
These data demonstrate that MEK/ERK are involved in invasion but not migration of PCa cells and suggest that 
PI3K-C2β can control cell invasion partly by regulating the MEK/ERK pathway and partly by activating addi-
tional signalling pathways that modulate PCa cell migration.
Figure 4. PI3K-C2β is involved in PCa cell invasion. (a,b) Serum starved PC3 cells were pre-treated with 
U0126 (25 μM) or vehicle alone (DMSO) for 30 min, detached and plated for FBS-induced invasion. Data in (a) 
are means ± s.e.m. from n = 3 independent experiments performed in duplicate. **p < 0.01. The same number 
of cells was plated in parallel in DMEM containing 10% FBS supplemented with U0126 (25 μM) or DMSO 
and counted after 48 h. Data in (b) are expressed as fold change of number of cells treated with DMSO and 
are means ± s.e.m. from n = 3 independent experiments performed in duplicate. (c) PC3 cells were plated in 
parallel with cells to be used in invasion assays, starved, pre-treated with the indicated concentrations of U0126 
for 30 min and then stimulated with FBS for 10 min in the presence or absence of the inhibitor. Phosphorylation 
of ERK1/2 was assessed by Western blotting. Tubulin was used as loading control. (d,e) PC3 cells were 
transiently transfected with the indicated siRNAs or transfection reagent alone (control), serum starved 
overnight the following day and then detached and plated for FBS-induced invasion assay. Data are expressed 
as average number of invaded cells/field and are means ± s.e.m. of n = 3 independent experiments performed 
in duplicate. **p < 0.01, *p < 0.05. (f,g) Data from FBS-induced invasion assays in all control (sh scrambled) 
and all knockdown (sh PI3K-C2β ) clones are pulled together and compared to parental PC3 cells and are 
means ± s.e.m. from n = 6 (PC3) and n = 8 (stable clones) independent experiments performed in duplicate. 
**p < 0.01 vs sh scrambled. Representative images for each clone are also shown in (f). (h) Results from basal 
invasion on Matrigel are means ± s.e.m. from n = 7 independent experiments performed in duplicate.  
(i) Results from EGF-induced invasion assays in the indicated cells are means ± s.e.m. from n = 3 independent 
experiments performed in duplicate. *p < 0.05. (j,k) FBS-induced invasion in LNCaP cells transiently 
transfected with the indicated siRNAs. Results are expressed as percentage of invaded cells transfected with 
siNC and are means ± s.e.m. of n = 3 independent experiments performed in duplicate. *p < 0.05, **p < 0.01. 
Efficiency of PI3K-C2β downregulation was assessed by Western blotting.
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PI3K-C2β specifically regulates the expression levels of the transcription factor Slug. In an 
effort to further characterise the signalling pathways regulated by PI3K-C2β and involved in cell migration/inva-
sion we next determined whether downregulation of this enzyme might affect the expression levels of proteins 
involved in epithelial-mesenchymal transition (EMT), a process by which epithelial cells can acquire migratory 
and invasive properties41. No major differences in the expression levels of the transcription factors TCF8/ZEB1 
(Supplementary Fig. S3a,b) and ZO-1 (Supplementary Fig. S3d,e), β catenin (Supplementary Fig. S3a,c), Vimentin 
(Supplementary Fig. S3d,f) and Claudin-1 (Supplementary Fig. S3g,h) was detected in sh PI3K-C2β compared 
to sh scrambled cells by Western blotting analysis. Similarly downregulation of PI3K-C2β did not affect mRNA 
levels of β catenin (Supplementary Fig. S3i), Vimentin (Supplementary Fig. S3j) and Twist (Supplementary Fig. 
Figure 5. PI3K-C2β is involved in PCa cell migration. (a,b) PC3 cells were transiently transfected with the 
indicated siRNAs. FBS-induced cell migration was assessed by Transwell assays. Data are means ± s.e.m. of 
n = 3 independent experiments performed in duplicate. *p < 0.05. (c) Results from FBS-induced migration 
assays in the indicated stable PC3 clones. Data are means ± s.e.m. of n = 3 independent experiments performed 
in duplicate. *p < 0.05. Representative images of Transwell inserts are also shown. (d,e) Representative images 
(d) and results (e) from wound healing assays in the indicated stable PC3 clones. Data are expressed as number 
of cells migrated into the wounded area and are means ± s.e.m. of n = 4 independent experiments. *p < 0.05. 
(f) Results from random motility assays in the indicated stable PC3 clones. Data indicate the mean velocity 
of single cells and are means ± s.e.m. of n = 3 (PC3, sh scrambled clones 3,4 and sh PI3K-C2β clone 3), n = 2 
(sh PI3K-C2β clone 2) and n = 1 (sh scrambled clone 2, sh PI3K-C2β clones 2,4) independent experiments. 
(g) Results from Type I collagen-induced migration assays in the indicated stable PC3 clones. Data are 
means ± s.e.m. of n = 3 independent experiments performed in duplicate. (h) Serum starved PC3 cells were 
pre-treated with U0126 (25 μM) or vehicle alone for 30 min before being detached and plated for FBS-induced 
migration assays in the absence or presence of the inhibitor. Data are means ± s.e.m. of n = 3 independent 
experiments performed in duplicate. (i) PC3 detached for cell migration as in (h) were re-plated in DMEM 
containing 10% FBS supplemented with U0126 or vehicle alone. Cells were counted at the end of the migration 
assays. Data are means ± s.e.m. of n = 3 independent experiments performed in duplicate. (j) PC3 cells were 
plated in parallel with cells to be used in migration assays, starved, pre-treated with the indicated concentrations 
of U0126 for 30 min and then stimulated with EGF (20 ng/ml) in the presence or absence of the inhibitor for 
10 min. Activation of ERK1/2 was assessed by Western blot. Tubulin was used as loading control.
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S3k) as assessed by qPCR analysis. On the other hand Western blotting analysis revealed a slight but significant 
reduction in the levels of the transcription factor Slug in stable sh PI3K-C2β clones compared to parental PC3 and 
sh scrambled cells (Fig. 6a,b). These data were confirmed upon transient downregulation of PI3K-C2β (Fig. 6c,d). 
Reduced levels of Slug mRNA were detected in all four sh PI3K-C2β stable clones (Fig. 6e). To determine whether 
reduced levels of Slug were associated with impaired cell invasion PC3 cells were transfected with a siRNA specif-
ically targeting the transcription factor (Fig. 6f–h). Consistent with previous reports42,43 downregulation of Slug 
significantly inhibited cell invasion (Fig. 6f) without affecting the total number of cells determined in parallel 
(Fig. 6g). Western blotting analysis confirmed reduced Slug levels in cells upon transfection (Fig. 6h). These data 
suggest that PI3K-C2β might further impact on cell migration and ultimately cell invasion by regulating Slug 
expression.
The PI3K-C2β-dependent regulation of Slug does not involve MEK/ERK activation. It has been 
recently reported that lipocalin 2 can induce Slug expression in 22RV1 PCa cells in a mechanism involving ERK 
activation44. We therefore determined whether MEK/ERK were also involved in Slug regulation in PC3 cells and 
whether the reduced Slug levels detected in stable PI3K-C2β knockdown clones was associated with the reduced 
FBS-dependent ERK activation observed in the same cells. First we observed that FBS stimulation for 24 h fol-
lowing overnight starvation was able to increase Slug expression levels in PC3 cells (Fig. 6i). In these conditions 
addition of U0126 did not appear to prevent stimulation of Slug expression (Fig. 6i). To better investigate mod-
ulation of Slug expression levels, serum-starved PC3 cells were incubated with cycloheximide (CHX) to inhibit 
protein synthesis for different times (Fig. 6j). We observed that incubation with CHX for 2 h was already able to 
strongly reduce Slug levels without affecting PI3K-C2β or ERK2 levels (Fig. 6j). We then treated serum starved 
PC3 cells for 2 h with CHX or vehicle (DMSO) alone before incubating them for 24 h in FBS in the presence or 
absence of MEK inhibitor U0126. Stimulation of cells with FBS for 24 h following 2 h treatment with DMSO or 
CHX strongly increased Slug protein levels (Fig. 6k,l - lanes I/III, II/V). In both cases simultaneous incubation 
with U0126 did not prevent the FBS-induced stimulation of Slug expression (Fig. 6k,l - lanes IV and VI), ruling 
out a main role for MEK/ERK in regulation of Slug expression in PC3 cells. Taken together these data suggest that 
PI3K-C2β modulates PCa cell migration and invasion by regulating distinct cellular processes, including MEK/
ERK activation and expression levels of the transcription factor Slug.
Discussion
Recent studies have greatly improved our understanding of the physiological roles of class II PI3K isoforms17 and 
they have contributed to establish that these enzymes are not redundant and can regulate distinct cellular func-
tions compared to other PI3Ks2. Despite this there is still a limited understanding of the signalling pathways that 
can be specifically regulated by each class II PI3K isoform.
Here we demonstrate that PI3K-C2β regulates FBS- and EGF-induced MEK/ERK activation in PCa cell lines. 
The observation that activation of ERK1/2 was not affected by treatment with LY294002 at a concentration able 
to inhibit class I and class III PI3Ks but not PI3K-C2β suggest a specific role for this isoform in MEK/ERK reg-
ulation. There are contrasting data in literature on the role of PI3K-C2β in ERK1/2 regulation. It was originally 
reported that transfection of HEK293 or COS-7 cells with either wild-type PI3KC2β or a kinase inactive mutant 
PI3KC2β DN construct did not affect EGF-induced ERK activation35. Similarly overexpression of PI3KC2β DN 
in H-69 SCLC cells did not inhibit the stem cell factor-induced ERK1/2 phosphorylation or activation assessed 
by in vitro kinase assay35. Consistent with these data, no effect on sphingosine 1-phosphate-dependent ERK1/2 
phosphorylation was detected in human umbilical vein endothelial cells upon downregulation of PI3KC2β using 
transient transfection of specific siRNA40 or in EGF-mediated ERK1/2 phosphorylation in SK-N-AS and IMR-5 
neuroblastoma cell lines stably infected with shRNAs targeting PI3KC2β 34. On the other hand both basal and 
EGF-mediated ERK1/2 activation appeared to be inhibited in A-431 cells overexpressing either wild type or 
kinase dead PI3KC2β D1213A-17 and D1213A-3232. Furthermore EGF- or platelet derived growth factor-induced 
ERK1/2 phosphorylation was increased in NIH3T3 overexpressing PI3KC2β and reduced in NIH3T3 overex-
pressing PI3KC2β DN36. Our data here indicate a specific role for PI3K-C2β in regulation of MEK/ERK in PCa 
cell lines PC3 and LNCaP. It is worth mentioning that PC3 and LNCaP are both PTEN null cells and appear to 
express increased levels of PI3K-C2β compared to the PTEN-expressing PCa cell line DU145 or the prostate 
cell line PNT2. Whether PI3K-C2β specifically regulates MEK/ERK in the context of PTEN deletion/mutation 
remains to be established.
We further show that downregulation of PI3K-C2β inhibited PCa cell invasion. While data have previously 
indicated a role for this enzyme in migration of several cell types31–33,37,40 this is the first study demonstrating 
that PI3K-C2β is required for PCa cell invasion. Importantly we observed that inhibition of MEK/ERK also 
reduced PCa cell invasion, consistent with a previous study suggesting that downregulation of ERK2 in PC3-ML, 
a subclone of PC3 able to metastasise to the lumbar vertebrae, resulted in reduced ability to form metastasis45. 
Taken together these data indicate that the PI3K-C2β -dependent MEK/ERK regulation is involved in regulation 
of PCa cell invasion. On the other hand neither PI3K-C2β nor MEK/ERK appear to play a main role in PCa cell 
proliferation, at least in normal growing conditions. Interestingly we observed that downregulation of PI3K-C2β 
resulted in a much stronger reduction of cell invasion compared to the effect of MEK/ERK inhibition. Indeed 
further investigation revealed that downregulation of PI3K-C2β reduced both FBS-induced cell migration and 
invasion whereas MEK/ERK inhibition impaired cell invasion without affecting cell migration. This is consistent 
with a previous report demonstrating that ERK1/2 is not involved in EGF-induced migration of prostate cancer 
cell line DU14546 and suggests that the PI3K-C2β -regulation of MEK/ERK is involved in steps necessary for cell 
invasion other than cell migration. In this respect it is noteworthy that ERK1/2 has been previously reported 
to play a key role in ADAM17-dependent invasion of PCa cell through overexpression of metalloproteinases 
MMP-2 and MMP-947.
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Figure 6. PI3K-Cβ regulates levels of the transcription factor Slug. (a,b) Representative blots and results 
from densitometry analysis expressed as fold change of normalised levels of Slug in the shscrambled clone 
used in each set of experiments. Data are means ± s.e.m. from n = 5–10 independent experiments. **p < 0.01, 
***p < 0.001 vs shscrambled. (c,d) Representative blots and results from densitometry analysis expressed as 
fold change of normalised levels of Slug in cells transfected with si NC. Data are means ± s.e.m. from: n = 4–5 
independent experiments. *p < 0.05. (e) Results from qPCR analysis expressed as fold change of normalised 
levels of Slug mRNA in PC3. Data are means ± s.e.m. from n = 3 independent experiments. shPI3K-C2β clone 
1: *p < 0.05 vs PC3 and shscrambled clone 4; shPI3K-C2β clone 2: *p < 0.05 vs shscrambled clone 4, #p < 0.01 
vs PC3 and shscrambled clone 2; shPI3K-C2β clone 3: *p < 0.05 vs shscrambled clone 4 and shscrambled clone 
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Taken together these data suggest that PI3K-C2β can control cell invasion partly by regulating the MEK/
ERK pathway and partly by activating additional signalling pathways that modulate PCa cell migration. It has 
been previously reported that PI3K-C2β can regulate cell motility by modulating activation of GTPases and 
actin remodelling32. Indeed PI3K-C2β has been recently identified as the main PI3K isoform involved in actin 
remodelling of ovarian cancer cells33 confirming its critical role in regulation of migration of these cells31,33. To 
further define the mechanisms involved in PI3K-C2β -dependent regulation of cell migration we investigated the 
potential contribution of this enzyme to EMT and we observed that downregulation of PI3K-C2β induced a spe-
cific reduction in the expression levels of the transcription factor Slug. Slug is a member of the Snail super family 
of zinc finger transcription factors that have a key role in EMT and in regulation of cell invasion and metastasis 
in several cancer types48–50. In particular we observed that downregulation of Slug inhibited invasion of PC3 
cells, consistent with a previous study42 and with a report demonstrating that overexpression of Slug stimulates 
migration and invasion of PC3 cells43. Moreover it was proposed that inhibition of Slug might represent one of the 
main mechanisms by which combination of mTOR, ERK1/2 and Hsp90 inhibitors was able to reduce circulating 
tumour cells in xenograft mouse models implanted with PCa cell lines51. Here we show that downregulation of 
PI3K-C2β results in reduced expression levels of Slug in PC3 cells and this is the first evidence of a role for a class 
II PI3K in regulation of the expression of this transcription factor. These results together with our and previous 
data demonstrating the role of Slug in migration and invasion strongly suggest that modulation of Slug levels may 
be one of the mechanisms by which PI3K-C2β regulates these cellular processes. Furthermore, as we ruled out a 
main role for MEK/ERK in Slug regulation in PC3 cells, these data demonstrate that PI3K-C2β can control PCa 
cell migration and invasion through different cellular pathways.
Taken together our study has identified novel signalling pathways specifically activated by PI3K-C2β and it 
has revealed an important role for this enzyme in PCa cells. It has been estimated that roughly 40% of primary 
and 70% of metastatic PCa have genomic alterations of PI3K-dependent signalling pathway52. Complete loss 
or haploinsufficiency of PTEN occurs in 20–70% of primary PCa and 30–80% of locally advanced and met-
astatic disease53. Animal models have indicated the pivotal role of PTEN in PCa54–56. Homozygous Pten-null 
mice develop prostate intraepithelial neoplasia (PIN) that do not evolve to more aggressive forms of the disease 
mostly because of simultaneous development of other tumours. On the other hand, homozygous deletion of 
Pten in the mouse prostate led to PIN lesions at 6 weeks of age that progressed to invasive and metastatic pros-
tate carcinoma within a few weeks55. The use of Pten hypomorphic alleles demonstrated that decreasing PTEN 
levels correlates with increased progression of prostate tumours in mice. Furthermore mouse models have also 
established that concurrent Pten hemizygosity coupled with deletions in other genes accelerates tumourigene-
sis. Further animal models revealed the critical role of the class I PI3K isoform p110β and not p110α in PTEN 
deletion-driven PCa development57. Indeed overexpression of p110β was able to induce early lesions of prostatic 
tumour formation in mice58. Several in vitro studies further confirmed the role of this enzyme and indicated a role 
in androgen-dependent gene expression, cell proliferation and survival59. Indeed a specific p110β inhibitor that 
has been modified to selectively target PCa cells has recently shown a very strong activity towards xenografts from 
different PCa cells60. As a consequence p110β is considered a very promising novel target in PCa59. Interestingly 
a recent study investigating the associations between single nucleotide polymorphisms in PI3K genes and PCa 
risk reported significant associations between a cluster of variants located upstream and in the promoter regions 
of PIK3C2B, the gene encoding for PI3K-C2β , and PCa risk38. Despite this interesting evidence, very little was 
known on the role of PI3K-C2β in PCa. Our data here demonstrate that PI3K-C2β is also a key enzyme in PCa, 
playing distinct roles and activating distinct cellular pathways compared to class I isoforms. Specifically, our data 
indicate that, while p110β has a key role in PCa cell proliferation and survival, PI3K-C2β is specifically involved 
in regulation of cell migration and invasion. These data suggest that PI3K-C2β may represent a novel potential 
target in PCa possibly to counteract metastasis progression. It is noteworthy that inhibition of this enzyme has 
been recently proved able to reduce ovarian cancer-derived metastasis formation in mice33, providing the first 
evidence of the anti-metastatic potential of targeting this enzyme.
In conclusion our study not only has identified novel signalling pathways specifically regulated by the class II 
PI3K isoform PI3K-C2β but it has also revealed a key role for this enzyme in PCa, in particular PCa cell migration 
and invasion.
Methods
Materials. Western blotting analyses were performed using the following antibodies: anti PI3K-C2α , 
anti PI3K-C2β (BD Transduction Laboratories); anti p110β , anti p110α , anti pERK1-2 (Thr202-Tyr204), anti 
2, #p < 0.01 vs PC3; shPI3K-C2β clone 4: *p < 0.05 vs shscrambled clone 4, #p < 0.01 vs PC3 and shscrambled 
clone 2. (f) Data from FBS-induced invasion assays in transiently transfected PC3 cells are expressed as average 
number of invaded cells/field and are means ± s.e.m. of n = 3 independent experiments performed in duplicate. 
*p < 0.05. (g) Data from cell counting performed in parallel with invasion assays are means ± s.e.m. of n = 4 
independent experiments in duplicate. (h) Efficient downregulation of Slug was assessed by Western blotting. 
(i) Serum starved PC3 cells were lysed (s.free) or incubated in FBS for 24 h in the presence or absence of U0126 
(25 μM) before lysis. (j) Serum starved PC3 were incubated with 50 μg/ml cycloheximide (CHX) or vehicle 
(DMSO) for the indicated times before lysis. (k,l) Serum starved PC3 cells were incubated with 50 μg/ml CHX 
or DMSO for 2 h and either lysed or incubated in FBS in the presence or absence of U0126 (25 μM) for further 
24 h before lysis. Data from densitometry analysis are expressed as fold change of normalised levels of Slug in 
cells treated with DMSO for 2 h and are means ± s.e.m. from n = 3 independent experiments. In (j,k) tubulin 
was used as loading control.
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pMEK1-2 (Ser217-221), anti PTEN, anti TCF8/ZEB1, anti ZO-1, anti β catenin, anti Vimentin, anti Claudin-1, 
anti Slug (Cell Signaling Technology); anti Tubulin, anti ERK2, anti Actin (Santa Cruz Biotechnology); anti 
GAPDH (Abcam); anti-rabbit IgG, anti-mouse IgG (Sigma Aldrich, UK). Transient downregulation of enzymes 
of interest was obtained using the following siRNAs: PI3K-C2β (sequence 1): AAGAATGCGACGCCTGGCAAG 
(Qiagen); PI3K-C2β (sequence 2): Cat. No. J-006772-08 (Dharmacon); p110β (Dharmacon, smartpoolA); Slug: 
Cat. No. J-017386-05 (Dharmacon). Non-targeting siRNAs (Ambion or Dharmacon), designated as ‘si NC’, were 
used as control.
Cell lines and transfections. PC3 and LNCaP cell lines were maintained in RPMI-1640 or Dulbecco’s 
modified Eagle’s medium (DMEM), DU145 cells in DMEM and PNT2 cells in RPMI-1640 without phenol red. 
Growth medium was supplemented with 10% (v/v) FBS, 1% (v/v) of 1X penicillin/streptomycin and glutamine 
and 1% (v/v) sodium pyruvate. All reagents were from Life Technologies. Cells were seeded in cell culture plates 
and left to grow in a humidified incubator at 37 °C, 5% CO2 atmosphere. Transient transfections of siRNAs were 
performed using OligofectAMINE (Life Technologies) according to the manufacturer’s instruction. To gener-
ate stable PC3 clones, cells were transfected with pSuper-based recombinant vectors containing either a shRNA 
specifically targeting PI3K-C2β (based on siRNA sequence 1) or a non-targeting shRNA (designated as ‘shRNA 
scrambled’) using LipofectAMINE (Life Technologies). Cell populations expressing the PI3K-C2β -targeting 
shRNA or shRNA scrambled were selected by incubation in growth media supplemented with 1.5 μg/ml puromy-
cin and then allowed to grow as single clones. Individual clones were then selected, amplified and subsequently 
cultured in the absence of puromycin.
Western blotting analysis. Cells were left in growth media or incubated overnight in serum free DMEM, 
supplemented with penicillin/streptomycin and L-glutamine before stimulation with FBS or 20 ng/ml EGF. Cells 
were then washed and lysed either in 2% SDS or in ice-cold lysis buffer [50 mM Tris, pH 7.5, 150 mM NaCl, 1% 
Triton X-100, 2 mM EDTA, 2 mM EGTA, 1 μl/ml Protease inhibitor cocktail (Sigma Aldrich), 1 μl/ml Phosphatase 
inhibitor cocktail A (Sigma Aldrich) and 1 μl/ml Phosphatase inhibitor cocktail B (Sigma Aldrich)]. For CHX 
(Sigma Aldrich) experiments, serum starved cells were incubated with serum free DMEM containing 50 μg/
ml CHX or vehicle (DMSO) for the indicated times. Cells were either lysed at different times or incubated with 
DMEM containing 10% FBS for further 24 h. Where indicated, MEK inhibitor U0126 (25 μM) was added to the 
media during the 24 h incubation period. Samples were separated by SDS-PAGE and transferred to nitrocellulose 
membranes. Membranes were then incubated in PBS supplemented with 0.05% (v/v) Tween 20 (PBS-T) and 
containing 5% skimmed milk powder for 30 min-1 h at room temperature, followed by overnight incubation with 
primary antibodies at + 4 °C. After washing with PBS-T membranes were incubated with secondary antibodies 
for 1 h at room temperature, washed with PBS-T and exposed to ECL reagent. Where indicated membranes were 
stripped by incubation at + 50 °C in SDS-based stripping buffer (62.5 mM Tris HCl pH 6.8, 0.5% SDS, 0.7% β 
mercapthoethanol) for 30 min. Densitometry was performed using Image J software.
Human phosphokinase array. Analysis of the phosphorylation status of several kinases and proteins 
was performed using Proteome Profiler Human Phospho-Kinase Array Kit (R&D Systems) according to the 
manufacturer’s instructions. Briefly, serum starved PC3 cells were either left untreated or incubated with FBS 
for 10 min. Cells were then washed in PBS and incubated with Lysis Buffer 6 for 30 min at + 4 °C. Cell debris 
were removed by centrifugation at 14,000 × g for 5 min and protein concentration was assessed by BCA Protein 
Assay. After blocking in Array Buffer 1 for 1 h at room temperature each membrane was incubated with 600 μg 
of cell lysate overnight at + 4 °C. Membranes were then washed with 1X Wash Buffer and incubated with diluted 
Detection Antibody Cocktail A and B for 2 h at room temperature followed by incubation with Streptavidin-HRP 
for additional 30 min. Membranes were then incubated with Chemi Reagent Mix and exposed on an X-ray film 
for 1–10 min. Densitometry analysis was performed using Image J software.
Cell Migration Assays. Random motility assay. Cells were plated in 6 well plates and transferred to an 
inverted contrast microscope (Zeiss Welwyn Garden City, UK) with a chamber of 37 °C, 5% CO2. Pictures were 
taken every 10 min for 15 h using a 10X phase contrast objective. Images were converted to movies and the motil-
ity of the cells was determined by the program MetaMorph® . All experiments were performed in duplicate.
Wound Healing Assay. Confluent cells were serum starved overnight. The following day, cells were wounded 
with a linear scratch using a sterile pipette tip in the presence of growth media supplemented with 10% FBS and 
0.5 μg/ml mitomycin C. Timelapse microscopy was performed for 12 h. Quantitative analysis was performed by 
positioning a red line at time 0 and time 12 and the number of cells that had migrated into the wound area was 
counted.
Transwell Assay. Cells were seeded in a 6 well plate and serum starved overnight. To determine the effect of tran-
sient downregulation of PI3K-C2β , cells were transfected with the specific siRNA and serum starved overnight 
the day following the transfection. Where indicated polycarbonate Transwell inserts (8.0 μm diameter pores, 
6.5 mm diameter, Costar® ) were coated overnight with 100 μg/ml Type I collagen (Sigma Aldrich) in PBS at 
+ 4 °C. Coated or uncoated inserts were then incubated in 500 μl RPMI supplemented with 0.5% BSA for 1 hour at 
37 °C/5% CO2 atmosphere. Cells were resuspended in RPMI supplemented with 0.5% BSA and plated on inserts 
(4,000 cells for collagen-induced migration; 12,000 or 20,000 cells for FBS-induced migration). The lower cham-
ber was filled with 500 μl of media supplemented with 10% FBS (uncoated inserts) or serum free media (coated 
inserts) and cells were left to migrate for 24 h (FBS) or 4 h (collagen) at 37 °C/5% CO2 atmosphere. Non-migrated 
cells were removed from the upper chamber using a cotton bud while cells that had migrated were fixed using 4% 
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paraformaldehyde for 30 min and stained with 0.1% crystal violet solution for 15 minutes. Pictures were taken 
from different fields using a light microscope at 10× magnification and cells were counted using the Image J pro-
gram. A minimum of 10 fields were counted. All experiments were performed in duplicate.
Cell Invasion Assay. Cells were seeded in a 6 well plate and serum starved overnight. To determine the 
effect of transient downregulation of PI3K-C2β or Slug, cells were transfected with the specific siRNA and serum 
starved overnight the day following the transfection. The following day, Matrigel pre-coated inserts (8.0 μm diam-
eter pores, 6.5 mm diameter, BD) were rehydrated by adding 500 μl of serum free RPMI or DMEM both in the 
lower and in the upper chamber for at least 1 hour at 37 °C/5% CO2 atmosphere. Cells were resuspended in 500 μl 
serum free media and homogeneously seeded in the upper chamber (30,000 cells/insert). The lower chamber 
was filled with 500 μl of media containing 10% FBS or serum free media supplemented with 20 ng/ml EGF. To 
determine basal invasion on Matrigel serum free media was added to the lower chamber. Cells were left to invade 
through the Matrigel for 48 h at 37 °C/5% CO2 atmosphere before being fixed, stained and counted as described 
above.
Cell Growth and Cell Cycle Assays. Cell Counting. Cells were seeded in 12 well plates and left in growth 
media. Cells were manually counted at the indicated times using a Burker chamber and a light microscope at 10x 
magnification. All experiments were performed in duplicate.
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cells were seeded in 12 well plates. At 
the indicated times, cells were incubated with 0.5 mg/ml of Thiazolyl Blue Tetrazolium Bromide (Sigma Aldrich) 
for 2 h at 37 °C, 5% CO2 atmosphere. After washing once with PBS, 350 μl of DMSO was added to the cells for 
15 min on a shaking rotor. The absorbance was read at 570–650nm using a spectrophotometer (HT Synergy). All 
experiments were performed in duplicate.
Cell Cycle Analysis – Vindellövs Propidium Iodide staining. Cells were seeded in a 6 well plate (150,000 cells/well) 
and transfected with the indicated siRNAs. After 72 h, cells were washed once with PBS, detached and collected in 
1.5 ml microfuge tubes and centrifuged at 1,200 rpm for 5 min. Pelleted cells were fixed in ice-cold 70% ethanol, 
washed three times in PBS, centrifuged for 5 min and resuspended in 500 μl Vindellövs Propidium Iodide solution 
(50 μg/ml). Cells were then analysed by flow cytometry collecting 20,000 events per sample using Fluorescence 
activated cell sorting (FACS) Diva software.
Apoptosis assay. Cells were plated in 6 well plates (150,000 cells/well) and transfected with the indicated 
siRNAs. At 48 h post transfection, cells were washed once with PBS and pelleted including the supernatant of the 
adherent cells. The pellet was resuspended in 400 μl 1X Annexin V Binding Buffer and 2 μl of Annexin V-FITC 
and incubated in the dark for 15 min at room temperature. Then, 4 μl of 4’,6-diamidino-2-phenylindole (DAPI) 
was added and the samples were analysed by flow cytometry collecting 20,000 events per sample using FACS 
Diva software. A control of unstained cells was incubated only with 1X Annexin V Binding Buffer and Annexin 
V-FITC or DAPI in order to set the quadrants.
qPCR analysis. RNA was extracted from cells using GeneJET RNA Purification Kit (Thermo Scientific) 
according to the manufacturer’s instructions. The complementary DNA (cDNA) synthesis was performed on ice 
using Maxima Reverse Transcriptase (Thermo Scientific) according to the manufacturer’s instructions. RT-qPCR 
was performed using 2X Maxima SYBR green/Fluorescein (Fermentas) qPCR mix and the ABI 7500 RT-QPCR. 
GAPDH cDNA was also amplified as an internal control. Primers for EMT markers were kindly provided by Prof 
Nullin Divecha (University of Southampton, UK). All experiments were performed in triplicate. The relative 
changes in gene expression quantification were calculated using the relative ddCT analysis mode of the ABI 7500 
Real-Time PCR system software.
Statistical analysis. Data are expressed as means ± s.e.m. Differences between groups were analysed by 
Student’s t test in Excel (paired, one-tailed distribution) and p < 0.05 was considered statistically significant.
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